{"id":25450,"date":"2026-06-24T14:06:00","date_gmt":"2026-06-24T12:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=f2a80daba673794189a57376eafad560"},"modified":"2026-06-24T14:06:00","modified_gmt":"2026-06-24T12:06:00","slug":"tecan-accelerates-data-driven-lab-journey-with-agentic-ai-developments-powered-by-nvidia","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=25450","title":{"rendered":"Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered by NVIDIA"},"content":{"rendered":"

M\u00c4NNEDORF, Switzerland--(BUSINESS WIRE)--Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA BioNeMo Agent Toolkit<\/a>. The NVIDIA BioNeMo Agent Toolkit enables AI agents to access scientific AI capabilities directly within the Introspect platform, helping laboratories to optimize operations. Agentic AI will allow laboratories to move beyond traditional monitoring and reactive troubleshooting toward proactive actions that help prevent issues before they impact performance, quality, or scientific outcomes. Early access to the enhanced Introspect platform is available, with applications focused on pharmaceutical, biotechnology, and clinical laboratory environments.<\/p><\/a><\/a>

\nA milestone in the collaboration announced<\/a> in March 2026, this Agentic AI development demonstrates advancement of Tecan and NVIDIA\u2019s shared vision of enabling Data-Driven Laboratories with AI-powered platforms designed to accelerate scientific discovery and improve laboratory productivity.<\/p>

\nAgentic AI introduces a new paradigm for laboratory operations. Rather than identifying problems after they occur, intelligent agents can continuously analyze laboratory data, workflows, and system performance to uncover hidden patterns that limit throughput, constrain scalability, or reduce operational efficiency. By transforming data into recommended actions, laboratories can accelerate decision-making, optimize resource utilization, and proactively improve overall productivity.<\/p>

\nMukta Acharya, Executive Vice President - Head of the Life Sciences Business division at Tecan:<\/b> \u201cAgentic AI has the potential to reshape how laboratories operate. By combining Tecan\u2019s laboratory expertise with NVIDIA\u2019s BioNeMo Agent Toolkit, we are enabling a new generation of intelligent laboratory solutions that can proactively support scientists, improve productivity, and help accelerate scientific outcomes.\u201d<\/i><\/p>

\nThe work with NVIDIA focuses also on the agentic guardrails required for the responsible and reliable deployment of AI in laboratory environments. These safeguards support transparency, reliability, and controlled automation, helping in the establishment of Agentic AI as a trusted technology to support key research and operational workflows.<\/p>

\nTecan and NVIDIA will continue to further develop the AI-enabled platforms that Data-Driven Laboratories need to achieve faster discoveries and higher lab productivity, including the use of Physical AI to enable Next-Gen Lab Instrumentation.<\/p>

\nFor more information about one of the use cases of this collaboration, please visit the Introspect landing page<\/a>.<\/p>

\nFor more details on NVIDIA BioNeMo Agent Toolkit and the broader AI drug discovery ecosystem, read the full NVIDIA announcement here: NVIDIA Announces BioNeMo Agent Toolkit \u2014 Tools for Agents to Accelerate Scientific Discovery<\/a>.<\/p> Contacts<\/b>

\nMedia contacts:<\/b>Dr Ben Rutter\nZyme Communications\nben.rutter@zymecommunications.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

M\u00c4NNEDORF, Switzerland–(BUSINESS WIRE)–Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDI…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25450","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25450"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25450\/revisions"}],"predecessor-version":[{"id":25451,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/25450\/revisions\/25451"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}